Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.63 |
| ▸ | ADCY6 | O43306 | 6/20 | 0.63 |
| ▸ | ADCY3 | O60266 | 6/20 | 0.63 |
| ▸ | ADCY9 | O60503 | 6/20 | 0.63 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.63 |
| ▸ | ADCY8 | P40145 | 6/20 | 0.63 |
| ▸ | ADCY7 | P51828 | 6/20 | 0.63 |
| ▸ | ADCY2 | Q08462 | 6/20 | 0.63 |
| ▸ | ADCY1 | Q08828 | 6/20 | 0.63 |
| ▸ | ADCY4 | Q8NFM4 | 6/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GCG | P01275 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528649 | 1.00 | GCGR (0.63) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21529041 | 0.89 | GCGR (0.58) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21529043 | 0.89 | GCGR (0.58) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528726 | 0.89 | GCGR (0.66) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528723 | 0.89 | GCGR (0.66) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528960 | 0.87 | GCGR (0.60) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528961 | 0.87 | GCGR (0.60) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21530800 | 0.85 | GCGR (0.57) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21530797 | 0.85 | GCGR (0.57) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2657984 | 0.84 | GCGR (0.64) | GCGRADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | claimed |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | GLP1R, IAPP, GPR119 | GCGR 4/4885ADCY6 68/4885ADCY3 25/4885 |
| US-11384060-B2 | Amide compounds and use thereof | GLP1R, IAPP, GPR119 | GCGR 4/4885ADCY6 68/4885ADCY3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.